Search

Your search keyword '"Hospital for Special Surgery"' showing total 12,871 results
Start Over Author "Hospital for Special Surgery"

Refine your results

more »

more »

more »

more »
12,871 results on '"Hospital for Special Surgery"'

2. STaR Trial: Multiple Ligament Knee Injuries

Author

Rhode Island Hospital, Hospital for Special Surgery, New York, Mayo Clinic, New York University, University of Cincinnati, University of Kentucky, University of Maryland, University of Michigan, University of Minnesota, University of Missouri-Columbia, University of New Mexico, University of Washington, Washington University School of Medicine, San Antonio Military Medical Center, Walter Reed National Military Medical Center, William Beaumont Army Medical Center, TRIA Orthopaedic Center, Wake Forest University, Unity Health Toronto, Western University, Canada, Ochsner Health System, Yale University, OrthoCarolina Research Institute, Inc., Louisiana State University Health Sciences Center Shreveport, Duke University, University of Calgary, Oregon Health and Science University, Wake Forest University Health Sciences, Orlando Health, Inc., Fraser Orthopaedic Institute, and James J. Irrgang, Professor and Chair, Department of Physical Therapy

Published
2024

4. Spine Procedures Assisted With RoboTics And Navigation (SPARTAN)

Author

Pediatric Orthopaedic Society of North America, Medtronic, Children's Hospital Colorado, Hospital for Special Surgery, New York, Children's Healthcare of Atlanta, Rainbow Babies and Children's Hospital, Dell Children's Medical Center of Central Texas, Cedars-Sinai Medical Center, Medical University of South Carolina Shawn Jenkins Children's Hospital, St. Louis Children's Hospital, and Daniel Hedequist, Principal Investigator

Published
2024

5. CHronic Nonbacterial Osteomyelitis International Registry (CHOIR)

Author

Boston Children's Hospital, Boston, MA, USA, Hospital for Special Surgery, New York, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, USA, Riley Children's Hospital, Indianapolis, IN, USA, University of North Carolina, Chapel Hill, NC, USA, Royal Children's Hospital, Melbourne, Australia, Hacettepe University, Ankara, Turkey, Bambino Gesù Children's Hospital, Rome, Italy, University of British Columbia, Vancouver, BC, Canada, Meyer Children's Hospital, Florence, Italy, Mansoura University, University of Utah, Salt Lake City, UT, USA, University of Iowa Carver College of Medicine, Iowa City, IA, USA, Ann & Robert Lurie Children's Hospital of Chicago, Chicago, IL, USA, Palacky University Olomouc Institute of Molecular and Translational Medicine, Olomouc, Czechia, Alder Hey Children's NHS Foundation Trust Hospital, Liverpool, UK, University of Calgary, Calgary, Alberta, Canada, and Yongdong (Dan) Zhao, Principle Investigator

Published
2024

11. One Stage Versus Two Stage For Periprosthetic Hip And Knee Infection

Author

The Cleveland Clinic, Hospital for Special Surgery, New York, Rothman Institute at Thomas Jefferson University, Midwest Orthopaedics Rush University Medical Center, Vanderbilt University, Emory University, University of Iowa, Carilion Clinic, University of Southern California, Ochsner Health System, Cleveland Clinic Florida, University of Utah, and University of California, San Francisco

Published
2024

13. Osteochondritis Dissecans of Knee Prospective Cohort

Author

Altona Children's Hospital, Boston Children's Hospital, Children's Hospital Medical Center, Cincinnati, Children's Health Andrews Institute for Orthopaedics & Sports Medicine, Children's Healthcare of Atlanta, Children's Hospital Colorado, Children's Hospital of Philadelphia, Children's Hospital and Health System Foundation, Wisconsin, Children's Mercy Hospital Kansas City, Connecticut Children's Medical Center, Hospital for Special Surgery, New York, Kaiser Permanente, Mayo Clinic, National University Hospital, Singapore, Rady Children's Hospital, San Diego, Stanford University, Tennessee Orthopedic Alliance, Texas Scottish Rite Hospital for Children, The Rocky Mountain Hospital for Children, The Hospital for Sick Children, Göteborg University, University of Minnesota/TRIA Orthopaedic Center, and Washington University School of Medicine

Published
2024

14. Chronic Pain in Rheumatoid Arthritis (CPIRA-2)

Author

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), University of Michigan, Hospital for Special Surgery, New York, University of Colorado, Denver, Johns Hopkins University, and Yvonne Lee, Associate Professor of Medicine and Preventive Medicine

Published
2024

16. BBD Longitudinal Study of Osteogenesis Imperfecta

Author

Shriners Hospitals for Children, Hospital for Special Surgery, New York, Children's National Research Institute, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., University of California, Los Angeles, Oregon Health and Science University, University of Nebraska, Alfred I. duPont Hospital for Children, University of South Florida, Phoenix Children's Hospital, and Brendan Lee, Professor and Chairman

Published
2023

17. Dental Malocclusion and Craniofacial Development in OI

Author

Shriners Hospitals for Children, Hospital for Special Surgery, New York, University of Nebraska, Hugo W. Moser Research Institute at Kennedy Krieger, Inc., Children's National Research Institute, University of California, Los Angeles, Oregon Health and Science University, and Brendan Lee, Professor and Chairman

Published
2023

20. Pediatric ACL: Understanding Treatment Options (PLUTO)

Author

Children's Hospital of Philadelphia, Children's Hospital Medical Center, Cincinnati, Rady Children's Hospital, San Diego, Washington University School of Medicine, Children's Healthcare of Atlanta, The Cleveland Clinic, Tennessee Orthopedic Alliance, Hospital for Special Surgery, New York, Stanford University, and Mininder Kocher, Principal Investigator

Published
2023

21. DIFFIR - Geriatric Distal Femur Fixation Versus Replacement (DIFFIR)

Author

Mount Sinai Hospital, Canada, NYU Langone Health, Brigham and Women's Hospital, Queen Elizabeth II Health Sciences Centre, Hamilton Health Sciences Corporation, Yale New Haven Health System Center for Healthcare Solutions, Oregon Health and Science University, OrthoCincy Orthopaedics & Sports Medicine, University of California, Rush University Medical Center, Rothman Institute Orthopaedics, Hospital for Special Surgery, New York, Stanford University, Cedars-Sinai Medical Center, Thunder Bay Regional Health Sciences Centre, University of California, San Francisco, University of Arkansas, University of Calgary, and Ascension Health

Published
2023

23. MOON Shoulder Instability-Cohort of Patients Undergoing Operative Treatment. (MOONSI)

Author

University of Michigan, University of California, San Francisco, University of Kentucky, Hospital for Special Surgery, New York, University of Colorado, Denver, Ohio State University, Washington University School of Medicine, Orthopedic Institute, Sioux Falls, SD, Vanderbilt University, Brigham and Women's Hospital, and Carolyn M Hettrich, Associate Professor

Published
2022

25. The Lupus prEGnAnCY Cohort: An International Prospective Cohort of Lupus Pregnancies (LEGACY)

Author

Duke University, University of California, Los Angeles, Dalhousie University, Hanyang University, Hospital for Special Surgery, New York, Johns Hopkins University, Monash University, New York University, Oklahoma Medical Research Foundation, University of North Carolina, Temple University, University of Alabama at Birmingham, University of Birmingham, University of Calgary, University of California, University of Copenhagen, University of Manitoba, University of Michigan, University of Toronto, NYU Langone Health, University of British Columbia, National Institute of Medical Science & Nutrition, Laval University, University Health Network, Toronto, and Evelyne Vinet, Principal Investigator

Published
2022

27. A Multicenter Prospective Study of Quality of Life in Adult Scoliosis (ASLS)

Author

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Northwestern University, New York University, University of Virginia, University of Louisville, Maryland Spine Center, Hospital for Special Surgery, New York, University Health Network, Toronto, Hopital du Sacre-Coeur de Montreal, and Dartmouth College

Published
2021

28. Long-Term Outcomes of Hip Interventions for Children With Cerebral Palsy (CHOP II)

Author

Royal Children's Hospital, Shriners Hospitals for Children,Canada, Provincial Health Services Authority, Aarhus University Hospital, Sheba Medical Center, Seoul National University Bundang Hospital, Starship Children's Hospital of New Zealand, Poznan University of Medical Sciences, Skane University Hospital, Karolinska University Hospital, Great Ormond Street Hospital for Children NHS Foundation Trust, The Royal London Hospital, Nuffield Orthopaedic Centre NHS Trust, Children's Hospital Medical Center, Cincinnati, Boston Children's Hospital, Columbia University, Shriners Hospitals for Children, Sacramento, Gillette Children's Specialty Healthcare, Alfred I. duPont Hospital for Children, IWK Health Centre, Alder Hey Children's NHS Foundation Trust, Children's Hospital Colorado, Hospital for Special Surgery, New York, Shriners Hospitals for Children, Honolulu, Robert Jones and Agnes Hunt Orthopaedic and District NHS Trust, Morgan Stanley Children's Hospital, Children's Health Queensland Hospital and Health Service, University of Nebraska, and Unni Narayanan, MBBS, MSc, FRSC(C)

Published
2021

29. Study of Two Surgical Drilling Techniques to Treat Juvenile Osteochondritis Dissecans of the Knee

Author

Pediatric Orthopaedic Society of North America, University of Pennsylvania, Tennessee Orthopedic Alliance, Children's Hospital Medical Center, Cincinnati, Children's Hospital and Health System Foundation, Wisconsin, Washington University School of Medicine, The Hospital for Sick Children, Children's Hospital of Philadelphia, Kaiser Permanente, Rady Children's Hospital, San Diego, St. Luke's Children's Hospital, Medical College of Wisconsin, Connecticut Children's Medical Center, Hospital for Special Surgery, New York, and Benton Heyworth, Instructor in Orthopaedic Surgery

Published
2020

30. Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

Author

Université de Sherbrooke, Institut de rhumatologie de Montréal, Hospital for Special Surgery, New York, University of Manitoba, University of Toronto, University of Alberta, University of British Columbia, Alberta Health services, McMaster University, The Arthritis Program Research Group, and Dr. Sasha Bernatsky, Principal Investigator

Published
2020

39. Health-related Quality of Life Measure in Pediatric Lupus

Author

Hospital for Special Surgery, New York, St. Barnabas Medical Center, Hackensack Meridian Health, University of Chicago, The Cleveland Clinic, Children's Hospital Los Angeles, Legacy Health System, University Hospitals Cleveland Medical Center, Tufts Medical Center, and University of Mississippi Medical Center

Published
2016

40. BLYS and IFN in SLE

Author

Hospital for Special Surgery, New York and W Winn Chatham

Published
2011

42. Solid malignancies among etanercept???treated patients with granulomatosis with polyangiitis (Wegener's): Long???term followup of a multicenter longitudinal cohort

Author

University of Michigan, Ann Arbor, Mayo Clinic, Rochester, Minnesota, Johns Hopkins University, Baltimore, Maryland, Massachusetts General Hospital, Boston, Boston University, Boston, Massachusetts, Cleveland Clinic, Cleveland, Ohio, Hospital for Special Surgery, New York, New York, University of California, San Francisco, Duke University Medical Center, Durham, North Carolina, Pontificia Universidad Catolica de Chile, Santiago, Chile, Thoracic Disease Research Unit, Stabile Building 8???56, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, Silva, Francisco, Seo, Philip, Schroeder, Darrell R., Stone, John H., Merkel, Peter A., Hoffman, Gary S., Spiera, Robert, Sebastian, Jodi K., Davis, John C., St.Clair, E. William, Allen, Nancy B., McCune, W. Joseph, Ytterberg, Steven R., Specks, Ulrich, University of Michigan, Ann Arbor, Mayo Clinic, Rochester, Minnesota, Johns Hopkins University, Baltimore, Maryland, Massachusetts General Hospital, Boston, Boston University, Boston, Massachusetts, Cleveland Clinic, Cleveland, Ohio, Hospital for Special Surgery, New York, New York, University of California, San Francisco, Duke University Medical Center, Durham, North Carolina, Pontificia Universidad Catolica de Chile, Santiago, Chile, Thoracic Disease Research Unit, Stabile Building 8???56, Division of Pulmonary and Critical Care Medicine, Mayo Clinic and Foundation, 200 First Street SW, Rochester, MN 55905, Silva, Francisco, Seo, Philip, Schroeder, Darrell R., Stone, John H., Merkel, Peter A., Hoffman, Gary S., Spiera, Robert, Sebastian, Jodi K., Davis, John C., St.Clair, E. William, Allen, Nancy B., McCune, W. Joseph, Ytterberg, Steven R., and Specks, Ulrich

Abstract

Objective An association between therapeutic inhibition of tumor necrosis factor (TNF) and solid malignancies was observed during the Wegener's Granulomatosis Etanercept Trial (WGET), which included 180 patients with granulomatosis with polyangiitis (Wegener's) (GPA). The present study was conducted to determine the malignancy risk beyond the time of exposure to study therapy. Methods The occurrence and type of solid malignancies were ascertained using a standardized data form. Data collected included vital status, histologic findings, and therapeutic interventions. The Surveillance, Epidemiology, and End???Results database was used to estimate a standardized incidence rate (SIR) for solid malignancies. Results Post???trial followup data were available for 153 patients (85% of the original cohort), with a median followup time of 43 months. Fifty percent of these patients had received etanercept. There were no differences in demographic characteristics between the etanercept and placebo groups. Thirteen new solid malignancies were detected, 8 in the etanercept group and 5 in the placebo group. Compared to the general population, the risk of solid malignancies in the etanercept group was increased (SIR 3.92 [95% confidence interval 1.69???7.72]), but was not different from the risk in the placebo group compared to the general population (SIR 2.89 [95% confidence interval 0.94???6.73]). All solid malignancies occurred in patients who had been exposed to cyclophosphamide. The overall duration of disease and a history of malignancy before trial enrollment were associated with the development of malignancy during post???trial followup. Conclusion The incidence of solid malignancy remained increased during long???term followup of the WGET cohort. However, this could not be attributed solely to etanercept exposure during the trial. Anti???TNF therapy with etanercept appears to further increase the risk of malignancy observed in patients with GPA treated with cytotoxic agent

Published
2011

43. A model to predict cardiovascular events in patients with newly diagnosed Wegener's granulomatosis and microscopic polyangiitis

Author

University of Michigan, Ann Arbor ; Dr. McCune has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Genentech and has received research support from Genentech and Human Genome Sciences., Nuffield Orthopaedic Centre, Oxford, UK ; Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7LD, UK, Oxford National Institute for Health Research and University of Oxford, Oxford, UK, Addenbrooke's Hospital, Cambridge, UK, University of Birmingham, Birmingham, UK, Lund University, Lund, Sweden, Norfolk and Norwich University Hospital, Norwich, UK, Genentech Corporation, South San Francisco, and University of California, San Francisco, Cleveland Clinic, Cleveland, Ohio, Boston University School of Medicine, Boston, Massachusetts, Duke University, Durham, North Carolina, Johns Hopkins University, Baltimore, Maryland, Hospital for Special Surgery, New York, New York, Massachusetts General Hospital, Boston, Nuffield Orthopaedic Centre, Oxford National Institute for Health Research, and University of Oxford, Oxford, UK, Suppiah, Ravi, Judge, Andrew, Batra, Rajbir, Flossmann, Oliver, Harper, Lorraine, H??glund, Peter, Javaid, M. Kassim, Jayne, David, Mukhtyar, Chetan, Westman, Kerstin, Davis, John C., Hoffman, Gary S., McCune, W. Joseph, Merkel, Peter A., St. Clair, E. William, Seo, Philip, Spiera, Robert, Stone, John H., Luqmani, Raashid, University of Michigan, Ann Arbor ; Dr. McCune has received consultant fees, speaking fees, and/or honoraria (less than $10,000) from Genentech and has received research support from Genentech and Human Genome Sciences., Nuffield Orthopaedic Centre, Oxford, UK ; Nuffield Orthopaedic Centre, Windmill Road, Headington, Oxford OX3 7LD, UK, Oxford National Institute for Health Research and University of Oxford, Oxford, UK, Addenbrooke's Hospital, Cambridge, UK, University of Birmingham, Birmingham, UK, Lund University, Lund, Sweden, Norfolk and Norwich University Hospital, Norwich, UK, Genentech Corporation, South San Francisco, and University of California, San Francisco, Cleveland Clinic, Cleveland, Ohio, Boston University School of Medicine, Boston, Massachusetts, Duke University, Durham, North Carolina, Johns Hopkins University, Baltimore, Maryland, Hospital for Special Surgery, New York, New York, Massachusetts General Hospital, Boston, Nuffield Orthopaedic Centre, Oxford National Institute for Health Research, and University of Oxford, Oxford, UK, Suppiah, Ravi, Judge, Andrew, Batra, Rajbir, Flossmann, Oliver, Harper, Lorraine, H??glund, Peter, Javaid, M. Kassim, Jayne, David, Mukhtyar, Chetan, Westman, Kerstin, Davis, John C., Hoffman, Gary S., McCune, W. Joseph, Merkel, Peter A., St. Clair, E. William, Seo, Philip, Spiera, Robert, Stone, John H., and Luqmani, Raashid

Abstract

Objective To create a prognostic tool to quantify the 5-year cardiovascular (CV) risk in patients with newly diagnosed Wegener's granulomatosis (WG) and microscopic polyangiitis (MPA) without premorbid CV disease. Methods We reviewed CV outcomes during the long-term followup of patients in the first 4 European Vasculitis Study Group (EUVAS) trials of WG and MPA. CV events were defined as CV death, stroke, myocardial infarction, coronary artery bypass graft, or percutaneous coronary intervention. Logistic regression was performed to create a model to predict the absolute risk of a CV event. The model was tested using the Wegener's Granulomatosis Etanercept Trial (WGET) cohort. Results Seventy-four (13.8%) of 535 patients with 5 years of followup from the EUVAS trials had at least 1 CV event: 33 (11.7%) of 281 WG versus 41 (16.1%) of 254 MPA. The independent determinants of CV outcomes were older age (odds ratio [OR] 1.45, 95% confidence interval [95% CI] 1.11???1.90), diastolic hypertension (OR 1.97, 95% CI 0.98???3.95), and positive proteinase 3 (PR3) antineutrophil cytoplasmic antibody (ANCA) status (OR 0.39, 95% CI 0.20???0.74). The model was validated using the WGET cohort (area under the receiver operating characteristic curve of 0.80). Conclusion Within 5 years of diagnosis of WG or MPA, 14% of patients will have a CV event. We have constructed and validated a tool to quantify the risk of a CV event based on age, diastolic hypertension, and PR3 ANCA status in patients without prior CV disease. In patients with vasculitis, PR3 ANCA is associated with a reduced CV risk compared to myeloperoxidase ANCA or negative ANCA status.

Published
2011

44. Assessment of the item selection and weighting in the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis

Author

University of Michigan, Ann Arbor, Boston University, Boston, Massachusetts, University of California, San Francisco, Cleveland Clinic, Cleveland, Ohio, Mayo Clinic, Rochester, Minnesota, Hospital for Special Surgery, New York, New York, Duke University Medical Center, Durham, North Carolina ; Dr. St.Clair has received consultant fees (less than $10,000 each) from Genentech, Biogen Idec, Medimmune, Xoma, and Human Genome Sciences., UptoDate, Waltham, Massachusetts, Boston University, Boston, Massachusetts ; Vasculitis Center, E5, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, Mahr, Alfred D., Neogi, Tuhina, Lavalley, Michael P., Davis, John C., Hoffman, Gary S., McCune, W. Joseph, Specks, Ulrich, Spiera, Robert F., St. Clair, E. William, Stone, John H., Merkel, Peter A., University of Michigan, Ann Arbor, Boston University, Boston, Massachusetts, University of California, San Francisco, Cleveland Clinic, Cleveland, Ohio, Mayo Clinic, Rochester, Minnesota, Hospital for Special Surgery, New York, New York, Duke University Medical Center, Durham, North Carolina ; Dr. St.Clair has received consultant fees (less than $10,000 each) from Genentech, Biogen Idec, Medimmune, Xoma, and Human Genome Sciences., UptoDate, Waltham, Massachusetts, Boston University, Boston, Massachusetts ; Vasculitis Center, E5, Boston University School of Medicine, 715 Albany Street, Boston, MA 02118, Mahr, Alfred D., Neogi, Tuhina, Lavalley, Michael P., Davis, John C., Hoffman, Gary S., McCune, W. Joseph, Specks, Ulrich, Spiera, Robert F., St. Clair, E. William, Stone, John H., and Merkel, Peter A.

Abstract

Objective To assess the Birmingham Vasculitis Activity Score for Wegener's Granulomatosis (BVAS/WG) with respect to its selection and weighting of items. Methods This study used the BVAS/WG data from the Wegener's Granulomatosis Etanercept Trial. The scoring frequencies of the 34 predefined items and any “other” items added by clinicians were calculated. Using linear regression with generalized estimating equations in which the physician global assessment (PGA) of disease activity was the dependent variable, we computed weights for all predefined items. We also created variables for clinical manifestations frequently added as other items, and computed weights for these as well. We searched for the model that included the items and their generated weights yielding an activity score with the highest R 2 to predict the PGA. Results We analyzed 2,044 BVAS/WG assessments from 180 patients; 734 assessments were scored during active disease. The highest R 2 with the PGA was obtained by scoring WG activity based on the following items: the 25 predefined items rated on ≥5 visits, the 2 newly created fatigue and weight loss variables, the remaining minor other and major other items, and a variable that signified whether new or worse items were present at a specific visit. The weights assigned to the items ranged from 1 to 21. Compared with the original BVAS/WG, this modified score correlated significantly more strongly with the PGA. Conclusion This study suggests possibilities to enhance the item selection and weighting of the BVAS/WG. These changes may increase this instrument's ability to capture the continuum of disease activity in WG.

Published
2008

45. Genetics of Bone Mineralization and Morphology in Inbred Mice: Analysis of the HcB/Dem Recombinant Congenic Strains

Author

HOSPITAL FOR SPECIAL SURGERY NEW YORK, Blank, Robert D., HOSPITAL FOR SPECIAL SURGERY NEW YORK, and Blank, Robert D.

Abstract

Susceptibility to osteoporotic fractures varies widely with genetic factors accounting for ^50% of this variation. Fracture risk is determined by peak bone mass and skeletal morphology achieved in young adulthood and the rate and extent of bone loss thereafter. This work will analyze the genetics of the first of these components through the use of recombinant congenic mice. We have demonstrated that the 27 HcB/Dem strains differ significantly in a variety of bone strength related phenotypes at 6 months of age. Further, preliminary mapping of genetic loci contributing to these phenotypes has been carried out. An intercross between HcB/13 and HcB/14 will allow more accurate mapping of a subset of these bone strength genes and investigation into pairwise epistatic interactions among loci. A cross examining Cola2(sup oim)/+ heterozygotes will allow determination of whether segregating differential loci in this system map to the same chromosomal regions identified in the HcB/Dem studies. Further breeding will be performed to develop true congenic lines and refine the mapping of the candidate genes for their positional cloning. Identifying mouse chromosome regions that control peak bone mineralization and morphology will allow prediction of the corresponding human regions by synteny and facilitate human genetic studies of this problem.

Published
2001

46. Postsurgical Rehabilitation Guidelines for the Orthopedic Clinician

Author

Hospital for Special Surgery, JeMe Cioppa-Mosca, Janet B. Cahill, Carmen Young Tucker, John Cavanaugh, Aviva L. Wolff, Deborah Corradi-Scalise, Holly B. Rudnick, Hospital for Special Surgery, JeMe Cioppa-Mosca, Janet B. Cahill, Carmen Young Tucker, John Cavanaugh, Aviva L. Wolff, Deborah Corradi-Scalise, and Holly B. Rudnick

Subjects
Rehabilitation, Medical rehabilitation, People with disabilities--Rehabilitation, Orthopedic surgery
Abstract

Designed to help therapists provide post-surgical rehabilitation based on best practices and evidence-based research, this comprehensive reference presents effective guidelines for postsurgical rehabilitation interventions. Its authoritative material is drawn from the most current literature in the field as well as contributions from expert physical therapists, occupational therapists, and athletic trainers affiliated with the Hospital for Special Surgery (HSS). A DVD accompanies the book, featuring over 60 minutes of video of patients demonstrating various therapeutic exercises spanning the different phases of postsurgical rehabilitation. Examples include hand therapy procedures, working with post-surgical patients with cerebral palsy, sports patient injuries, and pediatric procedures for disorders such as torticollis. - Material represents the best practices of experts with the Hospital of Special Surgery, one of the best known and most respected orthopedic hospitals. - Phases of treatment are defined in tables to clearly show goals, precautions, treatment strategies and criteria for surgery. - Many of the treatment strategies are shown in videos on the accompanying DVD, enabling the user to watch the procedure that is discussed in the text. - Information on pediatric and geriatric patients explores differing strategies for treating these populations. - Treatments specific to sports injuries are presented, highlighting the different rehabilitation procedures available for athletes. - An entire section on hand rehabilitation provides the latest information for hand specialists. - Information on the latest treatment strategies for hip replacement presents complete information on one of the most common procedures. - Easy-to-follow guidelines enable practitioners to look up a procedure and quickly see the recommended rehabilitation strategy. - A troubleshooting section provides solutions for common problems that may occur following each phase of the rehabilitation process. - Broad coverage addresses both traditional techniques as well as newer methods in a single resource. - Clear photos and illustrations show how to correctly perform the techniques described in the book.

Published
2006

47. Outcomes after arthroscopic repair of type-II SLAP lesions.

Author

Brockmeier SF, Voos JE, Williams RJ 3rd, Altchek DW, Cordasco FA, Allen AA, Hospital for Special Surgery Sports Medicine and Shoulder Service, Brockmeier, Stephen F, Voos, James E, Williams, Riley J 3rd, Altchek, David W, Cordasco, Frank A, and Allen, Answorth A

Subjects
SHOULDER joint surgery, SHOULDER joint injuries, SPORTS re-entry, ARTHROSCOPY, SHOULDER injuries, PATIENT satisfaction, SPORTS injuries, SURGICAL complications, TREATMENT effectiveness, DESCRIPTIVE statistics, WOUNDS & injuries, EVALUATION
Abstract

Background: To our knowledge, there has been no prospective study on the results of arthroscopic repair of superior labrum-biceps anchor complex (SLAP) tears with use of modern techniques. The purpose of the present study was to prospectively evaluate the minimum two-year results for patients with type-II SLAP tears that were treated with arthroscopic suture anchor fixation.Methods: Forty-seven patients with symptomatic type-II SLAP tears were evaluated preoperatively and at least two years postoperatively with use of the American Shoulder and Elbow Surgeons (ASES) and L'Insalata outcomes instruments and physical examination. The study group included thirty-nine male and eight female patients with a mean age of thirty-six years; thirty-four of the forty-seven patients were athletes. Patients with rotator cuff tears requiring repair or concomitant shoulder instability were excluded.Results: At an average of 2.7 years, the median ASES and L'Insalata scores were 97 and 93, respectively, compared with baseline scores of 62 and 65 (p < 0.05). The median patient-reported satisfaction rating was 9 (of 10); forty-one patients (87%) rated the outcome as good or excellent. The median patient-reported satisfaction rating was significantly higher for patients with a discrete traumatic etiology than for those with an atraumatic etiology (9 compared with 7); however, there was no significant difference between these groups in terms of the ASES or L'Insalata outcome scores. Overall, twenty-five (74%) of the thirty-four athletes were able to return to their preinjury level of competition, whereas eleven (92%) of the twelve athletes who reported a discrete traumatic event were able to return to their previous level of competition. There were five complications, including four cases of refractory postoperative stiffness.Conclusions: Our findings indicate that favorable outcomes can be anticipated in the majority of patients after arthroscopic SLAP lesion repair. While only three of four patients overall may be capable of returning fully to their previous level of competition, patients with a distinct traumatic etiology have a greater likelihood of a successful return to sports. [ABSTRACT FROM AUTHOR]

Published
2009
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results